---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-280620"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:28:53.704495+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma appoints Daniel G. Wildman to board of directors

## Summary
- Daniel G. Wildman appointed to fill a board vacancy effective November 8, 2022.
- Initial option grant of 20,000 ordinary shares, vesting in equal quarterly installments over 12 quarters.
- Annual retainer of $40,000 for board service plus $5,000 for service on the Compliance Committee.
- Eligible for annual option grant of 10,000 ordinary shares at each annual shareholder meeting.

## SEC filing metadata
- accession: 0001193125-22-280620
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/0001193125-22-280620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/d353119d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-280620
- JSON: https://secwatch.observer/filing/0001193125-22-280620.json
- Plain text: https://secwatch.observer/filing/0001193125-22-280620.txt

## Key facts
- Executive change
  Daniel G. Wildman was appointed as Director at UroGen Pharma Ltd..
  - Action: appointed
  - Role: Director
  source text: On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/0001193125-22-280620-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.